Samsung Bioepis expands biosimilar pipeline through Sandoz deal. The South Korean biotech company has signed a global development and commercialization agreement covering up to five biosimilar candidates, including SB36, which references Entyvio for immunology treatment. Samsung Bioepis will handle development and manufacturing while Sandoz manages commercialization across global markets excluding China and other Asian territories. This partnership strengthens both companies' positions in the growing biosimilar market, which offers more affordable alternatives to expensive biologic drugs. The collaboration focuses on immunology and oncology sectors, addressing patient access to critical medicines worldwide.
Post from MarketNews_en
Log in to interact with content.